Results 111 to 120 of about 8,187 (238)

Efficacy of Cefiderocol Against Endophthalmitis Isolates

open access: yes
Background/Objectives: Endophthalmitis is an intraocular microbial infection that can lead to permanent blindness, even with prompt anti-microbial therapy.
Jonathan B. Mandell   +6 more
core   +1 more source

The Efficacy of Topical Cefiderocol Treatment of Experimental Extensively Drug-Resistant Pseudomonas aeruginosa Keratitis Is Dependent upon the State of the Corneal Epithelium

open access: yesAntibiotics
Background: An overlooked factor in the efficacy of topical antibiotics to treat bacterial keratitis is the state of the corneal epithelium. Recently, we evaluated topical cefiderocol for the treatment of extensively drug-resistant (XDR) Pseudomonas ...
Eric G. Romanowski   +3 more
doaj   +1 more source

Outbreak of High-Risk Clone ST323 Klebsiella pneumoniae Resistant to Ceftazidime–Avibactam Due to Acquisition of blaVEB-25 and to Cefiderocol Due to Mutated fiu Gene

open access: yesAntibiotics
Background/Objectives: The incidence of Ceftazidime/Avibactam (CZA)-resistant Klebsiella pneumoniae isolate co-producing Klebsiella pneumoniae carbapenemase 2 (KPC-2) and Vietnamese extended-spectrum β-lactamase 25 (VEB-25) has been on the rise in Greece
I. Galani   +6 more
semanticscholar   +1 more source

Exploring the evidence for use of cefiderocol as part of combination therapies: A systematic review of

open access: yesJournal of Global Antimicrobial Resistance
Background: Cefiderocol is a siderophore cephalosporin with potent activity against carbapenem-resistant gramme-negative bacteria (CR-GNB). While monotherapy is recommended for susceptible Enterobacterales and Pseudomonas aeruginosa , the role of ...
Marco Meroi   +10 more
doaj   +1 more source

In vitro antimicrobial activity and resistance mechanisms of cefiderocol against clinical carbapenem-resistant gram-negative bacteria

open access: yesFrontiers in Microbiology
Background The rise of carbapenem-resistant gram-negative bacteria (CRGNB) necessitates new therapeutic options such as cefiderocol. Objective To evaluate the in vitro efficacy of cefiderocol against clinical CRGNB and investigate associated resistance ...
Ruyu Yan   +6 more
semanticscholar   +1 more source

Effectiveness and Safety of Cefiderocol in Clinical Practice for Treatment of Patients with Gram-Negative Bacterial Infections: US Interim Results of the PROVE Study [PDF]

open access: yes
Cornelius J Clancy,1 Oliver A Cornely,2– 4 Stephen W Marcella,5 Sean T Nguyen,6 Laurence Gozalo,7 Bin Cai8 1Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; 2Institute of Translational Research, Cologne Excellence Cluster on ...
Cai B   +5 more
core  

The Achilles’ heel of the Trojan Horse? A systematic evaluation of cefiderocol susceptibility testing

open access: yesJournal of Antimicrobial Chemotherapy
Cefiderocol, an innovative siderophore cephalosporin, presents a novel therapeutic option against a spectrum of multidrug-resistant (MDR) Gram-negative pathogens.
D. Tsakri   +5 more
semanticscholar   +1 more source

Carbapenem- and cefiderocol-resistant Enterobacterales in surface water in Kumasi, Ashanti Region, Ghana [PDF]

open access: yes
Background: MDR pathogens including ESBL- and/or carbapenemase-producing Enterobacterales (ESBL-PE and CPE) increasingly occur worldwide in the One Health context.
Eger, Elias   +9 more
core   +1 more source

In vitro activity of cefiderocol against Gram-negative aerobic bacilli in planktonic and biofilm form–alone and in combination with bacteriophages

open access: yesScientific Reports
Multi-drug resistant Gram-negative pathogens are increasingly difficult-to-treat perpetrators of infections. New, innovative, and more multifaceted therapies for the treatment of multi-drug resistant strains are thus urgent to hinder further drug ...
Rima Fanaei Pirlar   +4 more
semanticscholar   +1 more source

Successful therapy of a newborn with Stenotrophomonas maltophilia nosocomial pneumonia with cefiderocol [PDF]

open access: yes
Cefiderocol is a new siderophore-beta-lactam antibiotic used for the treatment of severe multidrug-resistant infections like sepsis, hospital-acquired and ventilator-associated pneumonia in adults, but there are only single reports on its use in the ...
Waitz, Markus   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy